Roche Holding AG Total Liabilities 2010-2023 | RHHBY

Roche Holding AG total liabilities from 2010 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Roche Holding AG total liabilities for the quarter ending December 31, 2023 were $63.721B, a 28.6% increase year-over-year.
  • Roche Holding AG total liabilities for 2023 were $63.721B, a 8.32% increase from 2022.
  • Roche Holding AG total liabilities for 2022 were $58.825B, a 15.95% decline from 2021.
  • Roche Holding AG total liabilities for 2021 were $69.992B, a 41.53% increase from 2020.
Roche Holding AG Annual Total Liabilities
(Millions of US $)
2023 $63,721
2022 $58,825
2021 $69,992
2020 $49,453
2019 $47,531
2018 $49,230
2017 $48,446
2016 $51,188
2015 $54,598
2014 $59,183
2013 $44,180
2012 $51,303
2011 $53,325
2010 $47,433
2009 $60,173
Roche Holding AG Quarterly Total Liabilities
(Millions of US $)
2023-12-31 $63,721
2022-12-31 $58,825
2022-06-30 $59,847
2021-12-31 $69,992
2021-06-30 $49,548
2020-12-31 $49,453
2020-06-30 $47,265
2019-12-31 $47,531
2019-06-30 $49,070
2018-12-31 $49,230
2018-06-30 $48,740
2017-12-31 $48,446
2017-06-30 $47,291
2016-12-31 $51,188
2016-06-30 $55,068
2015-12-31 $54,598
2015-06-30 $52,789
2014-12-31 $59,183
2014-06-30 $47,803
2013-12-31 $44,180
2013-06-30 $45,997
2012-12-31 $51,303
2012-06-30 $50,844
2011-12-31 $53,325
2011-06-30 $51,075
2010-12-31 $47,433
2010-06-30 $50,670
2009-12-31 $60,173
2009-06-30 $65,937
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $231.838B $65.370B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $688.937B 71.36
Johnson & Johnson (JNJ) United States $353.993B 14.36
Novo Nordisk (NVO) Denmark $353.124B 25.47
AbbVie (ABBV) United States $303.171B 15.96
Merck (MRK) United States $247.702B 16.46
AstraZeneca (AZN) United Kingdom $206.533B 17.57
Novartis AG (NVS) Switzerland $199.351B 13.25
Pfizer (PFE) United States $149.042B 10.19
Sanofi (SNY) $128.770B 11.66
Bayer (BAYRY) Germany $21.338B 3.42
Innoviva (INVA) United States $1.163B 9.68